STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more

STAT News · Mar 2, 2026 · Collected from RSS

Full Article

By Ed SilvermanMarch 2, 2026 Pharmalot Columnist, Senior Writer Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has predictably returned. You knew this would happen, though, so being a little Zen might help. And so would a few cups of stimulation. Our choice today is peppermint mocha. Feel free to join us. Remember, no prescription is required. Meanwhile, here is a menu of tidbits to help you along. Best of luck conquering the world today and, of course, do keep in touch. … The most-favored nation drug pricing deals the Trump administration reached with 16 drugmakers end after three years, in some cases, STAT reports. The agreements vary by each company, but there are several commonalities. Companies must participate in TrumpRx to provide some products at discounted prices for cash-paying customers; sell existing drugs to Medicaid at prices available in peer countries, excluding certain products; set U.S. launch prices at parity to those in reference countries; and return a portion of increased international revenues to the U.S if the Trump administration succeeds in increasing drug prices abroad. In return, companies avoid tariffs for three years. The three-year exemption led many to believe that the rest of the deal was time-limited, but that detail was not clear until companies disclosed it in regulatory filings. President Trump has for a year demanded that wealthy countries in Europe spend more on medicines so the U.S. can pay less and his campaign has introduced a new period of uncertainty across the continent, STAT explains. While there is little evidence that the prices of medications in Europe have yet been jacked up, countries are facing questions about whether drugmakers will try to charge more and how strained health systems will respond. There are also questions about what it could mean for access to medicines for patients, with the industry openly threatening to withhold drugs from markets that will not meet their demands for higher prices — or, in pharmaceutical parlance, to properly value innovation. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe